financetom
Business
financetom
/
Business
/
Sylogist Q3 revenue down 4.2%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sylogist Q3 revenue down 4.2%
Nov 6, 2025 3:28 AM

Overview

* Sylogist ( SYZLF ) fiscal Q3 total revenue declines 4.2% yr/yr

* SaaS subscription revenue grows 11.9% yr/yr, reflecting transformation to SaaS-driven enterprise

* Adjusted EBITDA margin at 19.3%, net income negative

Outlook

* Company did not provide specific financial guidance for future quarters

Result Drivers

* PARTNER STRATEGY - 48% of ARR Bookings in Q3 were partner-driven, indicating strong traction with partner strategy, per CEO Bill Wood

* RECURRING REVENUE - Co reports 72% of total revenue as recurring, reflecting a shift from lower margin, one-time project services

* SaaS ARR GROWTH - SaaS ARR increased 15% yr/yr to C$33.6 mln, supporting the company's SaaS transformation

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Gross 60.00%

Margin

Q3 C$0.01

Dividend

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy"

* Wall Street's median 12-month price target for Sylogist Ltd ( SYZLF ) is C$10.50, about 48.5% above its November 5 closing price of C$5.41

* The stock recently traded at 395 times the next 12-month earnings vs. a P/E of 71 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Australia's 'maze of uncertainty' scuttles $40 billion worth of M&A, clouds outlook
Australia's 'maze of uncertainty' scuttles $40 billion worth of M&A, clouds outlook
Sep 24, 2025
SYDNEY (Reuters) -Nearly $40 billion worth of big ticket buyouts have collapsed in Australia this year - the most in fifteen years - as regulatory risk and misaligned valuations add to the growing challenges in navigating an increasingly stringent regulatory environment. An ADNOC-led consortium's decision to walk away from its $18.7 billion bid for Santos , Australia's second largest gas...
Apollo Global Management Gets Approval for 3 New Evergreen ELTIF Funds in Europe
Apollo Global Management Gets Approval for 3 New Evergreen ELTIF Funds in Europe
Sep 24, 2025
04:04 AM EDT, 09/24/2025 (MT Newswires) -- Apollo Global Management ( APO ) said Wednesday that it has received regulatory approval from Luxembourg's Commission de Surveillance du Secteur Financier to launch three new evergreen, semi-liquid European Long-Term Investment Funds. The company said the new funds include Apollo European Private Credit ELTIF, which will focus on first-lien, senior secured direct lending...
Eli Lilly's boss calls UK the 'worst' European country for drug prices
Eli Lilly's boss calls UK the 'worst' European country for drug prices
Sep 24, 2025
* CEO says UK's drug pricing is lowest in Europe * Merck ( MRK ) and AstraZeneca ( AZN ) halt UK investments over pricing issues * UK claims commitment to making Britain a top life sciences hub By Muvija M LONDON, Sept 24 (Reuters) - Eli Lilly ( LLY ) Chief Executive Dave Ricks said Britain was probably the...
GE Healthcare, Lantheus Strike Licensing Deal for Prostate Cancer Imaging Agent in Japan
GE Healthcare, Lantheus Strike Licensing Deal for Prostate Cancer Imaging Agent in Japan
Sep 24, 2025
04:06 AM EDT, 09/24/2025 (MT Newswires) -- GE Healthcare Technologies ( GEHC ) has agreed to develop, manufacture and commercialize Lantheus' ( LNTH ) piflufolastat F18 for prostate cancer diagnostics and companion diagnostic use in Japan, the companies said Wednesday. Under the exclusive licensing agreement, GE Healthcare ( GEHC ) will pay Lantheus ( LNTH ) an upfront license fee,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved